Eli Lilly

LLY

Market cap $1.05T

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.

LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.

Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.

Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound.

CNBC's Jim Cramer delivers his daily Mad Dash.

Novo Nordisk (NYSE:NVO) stock is down 1% at $49.14, after the drugmaker filed a lawsuit against rival Eli Lilly (LLY), citing misleading advertising for its GLP-1 drugs.

Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly's products.

Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss drugs. The lawsuit, filed Tuesday in the US District Court for the District of New Jersey, alleges that Eli Lilly and Lilly USA violated federal and state false advertising and unfair competition laws, including the Lanham Act.

The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.